These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 16594908)

  • 1. Genetically determined apo B levels and peak LDL density predict angiographic response to intensive lipid-lowering therapy.
    Zambon A; Brown BG; Hokanson JE; Motulsky AG; Brunzell JD
    J Intern Med; 2006 Apr; 259(4):401-9. PubMed ID: 16594908
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evidence for a new pathophysiological mechanism for coronary artery disease regression: hepatic lipase-mediated changes in LDL density.
    Zambon A; Hokanson JE; Brown BG; Brunzell JD
    Circulation; 1999 Apr; 99(15):1959-64. PubMed ID: 10208998
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B.
    Brown G; Albers JJ; Fisher LD; Schaefer SM; Lin JT; Kaplan C; Zhao XQ; Bisson BD; Fitzpatrick VF; Dodge HT
    N Engl J Med; 1990 Nov; 323(19):1289-98. PubMed ID: 2215615
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Benefits of lipid-lowering therapy in men with elevated apolipoprotein B are not confined to those with very high low density lipoprotein cholesterol.
    Stewart BF; Brown BG; Zhao XQ; Hillger LA; Sniderman AD; Dowdy A; Fisher LD; Albers JJ
    J Am Coll Cardiol; 1994 Mar; 23(4):899-906. PubMed ID: 8106695
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Common hepatic lipase gene promoter variant determines clinical response to intensive lipid-lowering treatment.
    Zambon A; Deeb SS; Brown BG; Hokanson JE; Brunzell JD
    Circulation; 2001 Feb; 103(6):792-8. PubMed ID: 11171785
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effect of the apolipoprotein E phenotype on cholesteryl ester transfer protein activity, plasma lipids and apolipoprotein A I levels in hypercholesterolaemic patients on colestipol and lovastatin treatment.
    Korhonen T; Hannuksela ML; Seppänen S; Kervinen K; Kesäniemi YA; Savolainen MJ
    Eur J Clin Pharmacol; 1999 Feb; 54(12):903-10. PubMed ID: 10192749
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of simvastatin and ciprofibrate alone and in combination on lipid profile, plasma fibrinogen and low density lipoprotein particle structure and distribution in patients with familial combined hyperlipidaemia and coronary artery disease.
    Kontopoulos AG; Athyros VG; Papageorgiou AA; Hatzikonstandinou HA; Mayroudi MC; Boudoulas H
    Coron Artery Dis; 1996 Nov; 7(11):843-50. PubMed ID: 8993943
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intensive combination drug therapy of familial hypercholesterolemia with lovastatin, probucol, and colestipol hydrochloride.
    Witztum JL; Simmons D; Steinberg D; Beltz WF; Weinreb R; Young SG; Lester P; Kelly N; Juliano J
    Circulation; 1989 Jan; 79(1):16-28. PubMed ID: 2642754
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genetics of apolipoprotein B and apolipoprotein AI and premature coronary artery disease.
    Zambon A; Brown BG; Deeb SS; Brunzell JD
    J Intern Med; 2006 May; 259(5):473-80. PubMed ID: 16629853
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Familial Hypercholesterolaemia Regression Study: a randomised trial of low-density-lipoprotein apheresis.
    Thompson GR; Maher VM; Matthews S; Kitano Y; Neuwirth C; Shortt MB; Davies G; Rees A; Mir A; Prescott RJ
    Lancet; 1995 Apr; 345(8953):811-6. PubMed ID: 7898227
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of intensive lipid-lowering therapy on the coronary arteries of asymptomatic subjects with elevated apolipoprotein B.
    Zhao XQ; Brown BG; Hillger L; Sacco D; Bisson B; Fisher L; Albers JJ
    Circulation; 1993 Dec; 88(6):2744-53. PubMed ID: 8252687
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Familial Hypercholesterolemia, Familial Combined Hyperlipidemia, and Elevated Lipoprotein(a) in Patients With Premature Coronary Artery Disease.
    Vikulova DN; Trinder M; Mancini GBJ; Pimstone SN; Brunham LR
    Can J Cardiol; 2021 Nov; 37(11):1733-1742. PubMed ID: 34455025
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Effect of combined treatment with lovastatin and colestipol on serum lipids and lipoproteins].
    Kłosiewicz-Latoszek L; Nowicka G; Szostak WB
    Wiad Lek; 1993 Aug; 46(15-16):581-5. PubMed ID: 7975581
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Use of niacin, statins, and resins in patients with combined hyperlipidemia.
    Brown BG; Zambon A; Poulin D; Rocha A; Maher VM; Davis JW; Albers JJ; Brunzell JD
    Am J Cardiol; 1998 Feb; 81(4A):52B-59B. PubMed ID: 9526815
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of lowering elevated LDL cholesterol on the cardiovascular risk of lipoprotein(a).
    Maher VM; Brown BG; Marcovina SM; Hillger LA; Zhao XQ; Albers JJ
    JAMA; 1995 Dec; 274(22):1771-4. PubMed ID: 7500507
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of heterozygous familial hypercholesterolemia with lipid-lowering drugs.
    Illingworth DR; Bacon S
    Arteriosclerosis; 1989; 9(1 Suppl):I121-34. PubMed ID: 2492189
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The familial hypercholesterolemia regression study: a randomized comparison of therapeutic reduction of both low-density lipoprotein and lipoprotein(a) versus low-density lipoprotein alone.
    Kitano Y; Thompson GR
    Ther Apher; 1997 May; 1(2):187-90. PubMed ID: 10225769
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of colestipol alone and in combination with simvastatin on apolipoprotein B metabolism.
    Gaw A; Packard CJ; Lindsay GM; Murray EF; Griffin BA; Caslake MJ; Colquhoun I; Wheatley DJ; Lorimer AR; Shepherd J
    Arterioscler Thromb Vasc Biol; 1996 Feb; 16(2):236-49. PubMed ID: 8620338
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of two lipid-lowering treatments on quantitative coronary angiographic endpoints.
    Mack WJ; Xiang M; Shircore AM; Selzer RH; Hodis HN; Azen SP
    Cardiovasc Drugs Ther; 2000 Aug; 14(4):411-8. PubMed ID: 10999648
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Small, dense LDL and elevated apolipoprotein B are the common characteristics for the three major lipid phenotypes of familial combined hyperlipidemia.
    Ayyobi AF; McGladdery SH; McNeely MJ; Austin MA; Motulsky AG; Brunzell JD
    Arterioscler Thromb Vasc Biol; 2003 Jul; 23(7):1289-94. PubMed ID: 12750118
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.